• metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
• mNSCLC - L1 - all population 5
• mNSCLC - L1 - EGFR mutant
• mNSCLC - L1 - PDL1 negative 1
• mNSCLC - L1 - PDL1 positive 14
• mNSCLC - L1 - TMB>10Mb 1
• non squamous cell - mNSCLC - L1
• non squamous - mNSCLC - L1 - all population 3
• non squamous - mNSCLC - L1 - PDL1 positive
• non squamous - mNSCLC - L1 - Wild Type (WT) 6
• squamous cell - mNSCLC - L1
• squamous - mNSCLC - L1 - all population 4
• squamous - mNSCLC - L1 - PDL1 positive
• squamous - mNSCLC - L1 - Wild Type (WT)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus pemetrexed and platin
• pembrolizumab based treatment
• pembrolizumab and pemetrexed plus platin
• pembrolizumab plus SoC

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs paclitaxel plus carboplatin
• vs carboplatin plus nab-paclitaxel
• vs pemetrexed plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs VEGF(R) inhibitor
• vs bevacizumab based treatment
• vs bevacizumab plus carboplatin and paclitaxel

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  non squamous - mNSCLC - L1 - Wild Type (WT);